An investigation into cosmetic surgery chains by KFF Health News and NBC News has prompted consumer warnings from industry groups representing plastic surgeons and a call for more transparency around physician disciplinary actions in California. The American Society of Plastic Surgeons, which represents 12,000 doctors, is now warning patients to “do their homework” before getting…
Western Massachusetts, a patchwork of rural communities and low-income cities, is a difficult place to find a primary care doctor if you don’t already have one. Frustrated patients often turn to online forums, asking for leads or advice on how to find a practice that is accepting new patients. One name repeatedly crops up in…
Nitra announced that it raised $187 million in the past six months. The AI-powered platform — which is now used by more than 700 clinics — manages payments, procurement, inventory, scheduling and insurance verification in a single platform. The post Nitra Rakes In $187M to Simplify the Business of Running a Healthcare Practice appeared first…
I was quoted in a recent article in Pharmaceutical Technology titled “Targeted therapies to join chemo as oncology treatment backbone“. An excerpt is below: Though payers could theoretically prioritise chemotherapy over the use of targeted treatments due to their lower price, Jason Shafrin, senior managing director of FTI’s Center for Healthcare Economics and Policy, notes…
Universal Health Services plans to acquire Talkspace for $835 million to create a national behavioral health platform that integrates virtual therapy with in-person care. The post Why UHS Is Acquiring Talkspace for $835M appeared first on MedCity News.
Matt Chance and Will Robinson discuss some of the ways LEAD builds on their experience in the high-needs track of the ACO REACH model, which ends in 2026
The virtual health company’s leaders are aiming for mental health revenues from members covered by insurers to reach an annual pace of $100 million by year’s end.
Povetacicept, a Vertex Pharmaceuticals immunology drug designed to block two targets, met the main goal of a Phase 3 clinical trial in the rare kidney disease immunoglobulin A nephropathy. The fusion protein came from Vertex’s acquisition of Alpine Immune Sciences, and analysts say the drug has best-in-class potential. The post Vertex Pharma to Seek Speedy…
La primera llamada llegó justo antes del Día de Acción de Gracias del año pasado. No reconoció el número, pero respondió de todos modos. “La persona dijo que era un oficial del Departamento de Investigaciones Criminales que trabajaba en un caso de tráfico de drogas y lavado de dinero”, recordó la mujer. Parecía saber mucho…
Polypharmacy is a cost and safety problem that is solvable. The right technology platform can reduce it by identifying risky regimens, route specific “stop/switch/consolidate” opportunities to clinicians, and track whether changes stick through refill and adherence patterns. The post Chronic Overmedication: The Polypharmacy Waste and Safety Problem appeared first on MedCity News.